Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA

La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, has been selected for oral and poster presentations at the upcoming 10^th Annual T-Cell Lymphoma Forum, to be held February 1-3, 2018, at Hilton La Jolla Torrey Pines in La Jolla, CA, USA.  Clinical data highlights as well as details of the presentations are outlined below:

Clinical Data Highlights:

• Tenalisib (RP6530) updated data from ongoing Phase I/Ib study:  Demonstrated highly promising single-agent clinical activity with acceptable safety in relapsed/refractory T-cell Lymphoma.
  • R/R Peripheral T-cell Lymphoma (R/R PTCL) objective response rate (ORR) = 50%
  • R/R Cutaneous T-cell Lymphoma (R/R CTCL) objective response rate (ORR) = 44%

Details of the oral presentation:

• Oral Presentation Title:  RP6530, a dual PI3K d/g inhibitor: Interim results of a Phase I/Ib Study in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma
  • Session:  6
  • Date:  Friday, February 2, 2018
  • Location:  Hilton La Jolla Torrey Pines, La Jolla, CA
  • Presenter:  Bradley Haverkos, MD, MPH, University of Colorado School of Medicine, Denver, CO

Details of the poster presentation:

• Poster Title:  Results of Ongoing Phase 1/1b study of RP6530, a dual PI3K d/g inhibitor in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
  • Date and Time:  Friday, February 2, 2018; 6:00 PM – 8:00 PM US PST
  • Location:  Ballroom Foyer, Hilton La Jolla Torrey Pines, La Jolla, CA
  • Presenter:  Auris Huen, MD, University of Texas MD Anderson Cancer Center, Houston, TX

About Tenalisib (RP6530):

Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.  Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations.  In preclinical studies, RP6530 reprograms macrophages from an immunosuppressive M2-like phenotype (pro-tumor) to an inflammatory M1-like state (anti-tumor), which can potentially enhance the activity of checkpoint inhibitors or overcome resistance to these drugs.  Tenalisib obtained US FDA Fast Track and Orphan-Drug Designations for treatment of peripheral T-cell lymphoma (PTCL). 

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders.  Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.  Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.  For additional information, please visit Rhizen’s website, www.rhizen.com.

Contact:	
Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone:  +1-267-207-5707
Email:  [email protected]